Rasagiline in daily clinical use: Results of a treatment study of Parkinson patients with a combination treatment;Rasagilin im klinischen alltag: Ergebnisse einer anwendungsbeobachtung bei Parkinson-patienten mit einer kombinationstherapie

Fortschritte der Neurologie Psychiatrie

Volumn 76, Issue 10, 2008, Pages 594-599

  Jost, Wolfgang H ^a   Klasser, M ^b   Reichmann, H ^c  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b Gwd Consult   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

MAO B inhibitors; Parkinson's disease; Rasagiline; Therapy

Indexed keywords

LEVODOPA; RASAGILINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARKINSON DISEASE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 55749086674     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038249     Document Type: Article

References (11)

1. Finberg JPM, Lamersdorf I, Commissiong JW et al. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm 1996; Suppl 48: 95-101
2. Mandel S, Weinreb O, Amit T et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivates. Brain Res Rev 2005; 48: 379-387
3. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566
4. Youdim MBH, Bar Am O, Yogev-Falach M et al. Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005; 79: 172-179
5. Bar Am O, Amit T, Youdim MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004; 355: 169-172
6. Youdim MBH, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-506
7. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO-study. Arch Neurol 2005; 62: 241-248
8. Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954
9. Stern MB, Marek KL, Friedman J et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov. Disord 2004; 19: 916-923
10. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol 2002; 59: 1937-1943
11. Lew MF, Hauser RA, Hurtig HI et al. Long-term Efficacy of rasagilin in Parkinson's disease patients. Poster 09, präsentiert beim 16. Intl. Congress on Parkinson's Disease and Related Disorders Berlin, 5.-9.Juni